Biogen Inc. Q1 2025 10-Q Filed
Ticker: BIIB · Form: 10-Q · Filed: 2025-05-01T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, biotechnology, revenue
TL;DR
Biogen Q1 2025 10-Q is in, check revenue for anti-CD20 and LEQEMBI.
AI Summary
Biogen Inc. filed its 10-Q for the period ending March 31, 2025. The company reported revenues from its anti-CD20 therapeutic programs and LEQEMBI collaboration. Specific financial figures for these segments and overall product revenues for Q1 2025 and Q1 2024 are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial performance data for Biogen, including revenue breakdowns for key therapeutic areas and collaborations, crucial for assessing the company's current financial health and future prospects.
Risk Assessment
Risk Level: medium — Biogen operates in the highly regulated and competitive pharmaceutical industry, facing risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 146,527,832 — Shares (Total shares outstanding as of the reporting period.)
Key Players & Entities
- BIOGEN INC. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250501 (date) — Filing date
- 225 BINNEY STREET, CAMBRIDGE, MA 02142 (address) — Company's business and mailing address
- LEQEMBI (product) — Key collaboration mentioned
FAQ
What were Biogen's total revenues for the first quarter of 2025?
The filing details revenues for specific segments like anti-CD20 therapeutic programs and LEQEMBI collaboration for Q1 2025, but a consolidated total revenue figure for the quarter is not explicitly stated in the provided snippet.
How do Q1 2025 revenues from anti-CD20 therapeutic programs compare to Q1 2024?
The filing indicates that revenues from anti-CD20 therapeutic programs for the period January 1, 2025, to March 31, 2025, are reported, and comparative data for the period January 1, 2024, to March 31, 2024, is also available for comparison.
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, meaning the filing covers the period ending March 31, 2025.
When was this 10-Q filing submitted to the SEC?
The filing was submitted on 20250501.
What is the company's primary business classification?
Biogen Inc. is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
From the Filing
0000875045-25-000018.txt : 20250501 0000875045-25-000018.hdr.sgml : 20250501 20250501164823 ACCESSION NUMBER: 0000875045-25-000018 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 134 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250501 DATE AS OF CHANGE: 20250501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19311 FILM NUMBER: 25903992 BUSINESS ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 7814642000 MAIL ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC. DATE OF NAME CHANGE: 20070427 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 10-Q 1 biib-20250331.htm 10-Q biib-20250331 0000875045 12/31 2025 Q1 false 146,527,832 374 159 181 xbrli:shares iso4217:USD iso4217:USD xbrli:shares biib:segment xbrli:pure biib:Employee utr:sqft biib:wholesaler biib:product 0000875045 2025-01-01 2025-03-31 0000875045 2025-04-30 0000875045 us-gaap:ProductMember 2025-01-01 2025-03-31 0000875045 us-gaap:ProductMember 2024-01-01 2024-03-31 0000875045 biib:Revenuesfromanticd20therapeuticprogramsMember 2025-01-01 2025-03-31 0000875045 biib:Revenuesfromanticd20therapeuticprogramsMember 2024-01-01 2024-03-31 0000875045 biib:LEQEMBICollaborationMember 2025-01-01 2025-03-31 0000875045 biib:LEQEMBICollaborationMember 2024-01-01 2024-03-31 0000875045 us-gaap:ProductAndServiceOtherMember 2025-01-01 2025-03-31 0000875045 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-03-31 0000875045 2024-01-01 2024-03-31 0000875045 2025-03-31 0000875045 2024-12-31 0000875045 us-gaap:NonrelatedPartyMember 2025-03-31 0000875045 us-gaap:NonrelatedPartyMember 2024-12-31 0000875045 us-gaap:RelatedPartyMember 2025-03-31 0000875045 us-gaap:RelatedPartyMember 2024-12-31 0000875045 us-gaap:NonrelatedPartyMember 2025-01-01 2025-03-31 0000875045 us-gaap:NonrelatedPartyMember 2024-01-01 2024-03-31 0000875045 us-gaap:RelatedPartyMember 2025-01-01 2025-03-31 0000875045 us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0000875045 2023-12-31 0000875045 2024-03-31 0000875045 us-gaap:PreferredStockMember 2024-12-31 0000875045 us-gaap:CommonStockMember 2024-12-31 0000875045 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000875045 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000875045 us-gaap:RetainedEarningsMember 2024-12-31 0000875045 us-gaap:TreasuryStockCommonMember 2024-12-31 0000875045 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000875045 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000875045 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000875045 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000875045 us-gaap:PreferredStockMember 2025-03-31 0000875045 us-gaap:CommonStockMember 2025-03-31 0000875045 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000875045 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000875045 us-gaap:RetainedEarningsMember 2025-03-31 0000875045 us-gaap:TreasuryStockCommonMember 2025-03-31 0000875045 us-gaap:PreferredStockMember 2023-12-31 0000875045 us-gaap:CommonStockMember 2023-12-31 0000875045 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000875045 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000875045 us-gaap:RetainedEarningsMember 2023-12-31 0000875045 us-gaap:TreasuryStockCommonMember 2023-12-31 0000875045 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000875045 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000875045 us-gaap:CommonStockMember 2024-